Stock Markets May 7, 2026 10:11 PM

Mobia Medical Sets IPO Price at $15, Aiming to Raise $150 Million

Austin-based maker of an FDA-approved VNS implant schedules Nasdaq listing and grants underwriters an overallotment option

By Caleb Monroe

Mobia Medical priced a 10 million-share initial public offering at $15 per share to raise approximately $150 million before fees. The Austin, Texas-based medical device company expects its common stock to begin trading on the Nasdaq Global Select Market under the ticker MOBI on May 8, 2026, with the offering due to close on May 11, 2026, subject to customary closing conditions.

Mobia Medical Sets IPO Price at $15, Aiming to Raise $150 Million

Key Points

  • Mobia Medical is offering 10 million shares at $15.00 per share to raise approximately $150 million before underwriting discounts and other expenses - impacts the capital markets and healthcare financing environment.
  • The company’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker MOBI on May 8, 2026; expected close is May 11, 2026, subject to customary closing conditions - relevant to equity markets and listing activity.
  • Mobia’s Vivistim Paired VNS System is FDA-approved and designed for improving upper limb function in chronic ischemic stroke survivors with moderate to severe impairments - pertinent to the medical devices and rehabilitation sectors.

Mobia Medical Inc. has priced its initial public offering at $15.00 per share, offering 10 million shares and targeting roughly $150 million in gross proceeds before underwriting discounts and other expenses, the company said.

The firm anticipates its common stock will start trading on the Nasdaq Global Select Market under the ticker symbol "MOBI" on May 8, 2026. The transaction is expected to formally close on May 11, 2026, contingent on customary closing conditions.

Under the terms of the offering, Mobia Medical has granted the underwriting syndicate a 30-day option to buy up to an additional 1.5 million shares at the initial offering price, less underwriting discounts and commissions. That option would allow underwriters to increase the total number of shares sold in the IPO within the prescribed period.

Leading the bookrunning roles for the offering are BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC. BTIG is listed as a passive bookrunner while Wolfe | Nomura Alliance is acting as a manager for the deal.

Headquartered in Austin, Texas, Mobia Medical develops medical devices focused on stroke rehabilitation. Its Vivistim Paired VNS System is an FDA-approved implantable device intended to improve upper limb function in people who survived chronic ischemic stroke and who have moderate to severe impairments of the upper extremity.

The company filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission in connection with the offering; that filing became effective on May 7, 2026, according to the company’s statement.

Investors and market participants should note the offering size, pricing and the underwriters’ overallotment option as they assess the immediate market supply of shares once trading begins. The company’s oversight and disclosure around the S-1 and its timing indicate the procedural steps completed ahead of the expected Nasdaq listing.


Offering snapshot

  • Shares offered: 10,000,000
  • Price per share: $15.00
  • Gross proceeds (approximate): $150 million before underwriting discounts and other expenses
  • Overallotment option: Up to 1,500,000 additional shares, exercisable for 30 days
  • Expected Nasdaq trading date: May 8, 2026 (ticker: MOBI)
  • Expected close date: May 11, 2026, subject to customary closing conditions

Risks

  • The offering’s completion is subject to customary closing conditions, so the anticipated May 11, 2026 closing date is not guaranteed - this affects capital markets timing and deal certainty.
  • Underwriters hold a 30-day option to purchase up to 1.5 million additional shares at the IPO price less discounts and commissions, which could increase share supply and affect post-listing market dynamics - relevant to investors and equity market liquidity.

More from Stock Markets

Nvidia CEO Jensen Huang Sees 27% Drop in Total Pay as Stock Awards Lose Value May 12, 2026 Activist Urges BWX Technologies to Revisit Shelved Reactor Plan, Sees Potential for Stock to Double May 12, 2026 S&P Moves Mexico’s Outlook to Negative, Citing Fiscal Strain and Tepid Growth May 12, 2026 Moody's Lowers Everforth Outlook to Negative Amid Elevated Leverage May 12, 2026 Moody's Moves Albemarle Outlook to Stable After Debt Cuts and Stronger Lithium Prices May 12, 2026